| Previous Close | 7.00 |
| Open | 7.00 |
| Bid | 6.90 x 0 |
| Ask | 7.24 x 0 |
| Day's Range | 6.74 - 7.01 |
| 52 Week Range | 3.13 - 7.50 |
| Volume | 4,550 |
| Avg. Volume | 9,133 |
| Market Cap | 89.657M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | 19.55 |
| EPS (TTM) | 0.36 |
| Earnings Date | Aug. 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.92 |
- Simply Wall St.
There's Reason For Concern Over BioSyent Inc.'s (CVE:RX) Price
When close to half the companies in Canada have price-to-earnings ratios (or "P/E's") below 16x, you may consider...
- ACCESSWIRE
LD Micro: 360 Companies--Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- GlobeNewswire
BioSyent Releases Q2 and H1 2020 Results
MISSISSAUGA, Ontario, Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2020. Key highlights include: * Second quarter (Q2) 2020 Net Revenues of $4,771,255 decreased by 7% versus Q2 2019 * First half (H1) 2020 Net Revenues of $10,834,101 increased by 12% versus H1 2019 * Q2 2020 Canadian Pharmaceutical Net Revenues of $4,415,900 decreased by 9% versus Q2 2019 * H1 2020 Canadian Pharmaceutical Net Revenues of $10,371,461 increased by 14% versus H1 2020 * No impairment losses recognized in Q2/H1 2020; during Q2/H1 2019, recognized one-time impairment loss on intangible assets of $424,941 * Q2 2020 EBITDA1 of $1,062,582 increased by 24% versus Q2 2019 * H1 2020 EBITDA1 of $3,060,569 increased by 48% versus H1 2019 * Q2 2020 Net Income After Taxes (NIAT) of $722,206 increased by 5% versus Q2 2019 * H1 2020 NIAT of $2,173,724 increased by 30% versus Q2 2019 * Q2 2020 NIAT percentage to Net Revenues of 15% compares to 13% in Q2 2019 * H1 2020 NIAT percentage to Net Revenues of 20% compares to 17% in H1 2019 * Q2 2020 Fully Diluted EPS of $0.06 was $0.01 higher than Q2 2019 Fully Diluted EPS of $0.05 * H1 2020 Fully Diluted EPS of $0.16 was $0.04 higher than H1 2019 Fully Diluted EPS of $0.12 * Fully Diluted EPS for the Trailing Twelve Months June 30, 2020 was $0.36 as compared to $0.32 for the Trailing Twelve Months ended June 30, 2019 * As at June 30, 2020, the Company had cash, cash equivalents, and short-term investments totalling $21,467,744 as compared to $21,973,477 as at December 31, 2019 – a 2% decrease * Total Shareholders’ Equity decreased by 3% to $25,089,286 at June 30, 2020 from $25,794,510 at December 31, 2019 * Return on Equity for the Trailing Twelve Months ended June 30, 2020 was 20% as compared to 18% for the Trailing Twelve Months ended June 30, 2019 * During Q2 2020, repurchased and cancelled a total of 332,400 common shares under a Normal Course Issuer Bid (NCIB) * During H1 2020, repurchased and cancelled a total of 594,275 common shares under the NCIBMr. René Goehrum, President and CEO of BioSyent, commented, “We experienced accelerated sales volumes in our Canadian pharmaceutical business in late March 2020 due to forward inventory purchasing by wholesalers and pharmacies prompted by COVID-19 uncertainty. As a result of this inventory accumulation in late March, sales volumes declined significantly in the month of April 2020 as trade inventory levels were rebalanced by our customers. We observed a normalization in sales volumes in our Canadian pharmaceutical business in the months of May and June 2020 such that on a year-to-date basis, sales growth was 14% for the first half of 2020 over the first half of 2019.”Mr. Goehrum continued, “In spite of the challenging business environment brought on by COVID-19, Q2 2020 marked BioSyent’s 40th consecutive profitable quarter. Our business remained profitable in every month of Q2 2020 with our brands showing resilience through the challenges of COVID-19. While our existing Canadian pharmaceutical business stabilized during the quarter, we also continued launch preparations and investments for the new Tibella® women’s health product and Combogesic® pain management product. We are excited to have successfully launched Tibella® in July 2020 with the product available for the first time to women across Canada. We look forward to reporting on the progress of Tibella® in the market as well as our ongoing launch preparations for Combogesic®.”The CEO’s presentation on the Q2 2020 Results is available at the following link: www.biosyent.com/q2-20/.The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2020 and 2019 will be posted on www.sedar.com on August 26, 2020. PDF Available: http://ml.globenewswire.com/Resource/Download/5ab4f831-d9e9-4af2-9e23-da3eb3e811c3PDF Available: http://ml.globenewswire.com/Resource/Download/0aa3f911-44bf-41b7-9a54-d134cc90edabFor a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.About BioSyent Inc.Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.As of the date of this press release, the Company has 12,808,170 common shares outstanding. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Comprehensive Income In Canadian DollarsQ2 2020Q2 2019% ChangeH1 2020H1 2019% Change Net Revenues4,771,2555,156,476-7%10,834,1019,635,29012% Cost of Goods Sold1,042,9601,085,653-4%2,304,0632,044,07713% Gross Profit3,728,2954,070,823-8%8,530,0387,591,21312% Operating Expenses and Finance Income/Costs2,765,3543,167,760-13%5,631,7395,409,4824% Net Income Before Taxes962,941903,0637%2,898,2992,181,73133% Tax (including Deferred Tax)240,735212,22013%724,575512,70741% Net Income After Taxes722,206690,8435%2,173,7241,669,02430% Net Income After Taxes % to Net Revenues15%13% 20%17% EBITDA1,062,582860,25924%3,060,5692,061,40548% EBITDA % to Net Revenues22%17% 28%21% 1. EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. BioSyent Inc. Interim Unaudited Condensed Consolidated Statements of Financial Position AS AT June 30, 2020 December 31, 2019% Change ASSETS Trade and other receivables$2,789,818$2,083,72334% Inventory 1,827,349 2,139,127-15% Prepaid expenses and deposits 551,947 648,781-15% Cash, cash equivalents and short-term investments 21,467,744 21,973,477-2% CURRENT ASSETS 26,636,858 26,845,108-1% Property and equipment 2,323,028 2,482,266-6% Intangible assets 966,040 1,023,378-6% Loans receivable 594,336 588,4671% Deferred tax asset 30,366 26,09516% TOTAL NON CURRENT ASSETS 3,913,770 4,120,206-5% TOTAL ASSETS$30,550,628$30,965,314-1% LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES$3,735,599$3,359,04111% NON CURRENT LIABILITIES 1,725,743 1,811,763-5% Long term debt - -0% Total Equity 25,089,286 25,794,510-3% TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$30,550,628$30,965,314-1% For further information please contact:Mr. René C. Goehrum President and CEO BioSyent Inc. E-Mail: investors@biosyent.com Phone: 905-206-0013 Web: www.biosyent.comThis press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
